Braak stage 1, 100% of pigmented neurons left
parkinsonconnecting

Gene record

CYP3A5

cytochrome P450 family 3 subfamily A member 5

translation score 0.56, read 2026-10-25; 1 sealed predictions, 0 held; 1 receipts.

Six readers

readerfoundscore
genetics
Open Targets
no genetic evidence; overall 0.01 from other evidence0.00
cell type
Human Protein Atlas
expressed broadly, no clear home in brain cells0.40
chemistry
Open Targets
compounds already reach it: cobicistat, ritonavir1.00
trials
ClinicalTrials.gov
no Parkinson's trials on record: an open field1.00
literature
PubMed
2 Parkinson's papers of 3,2150.85
pathways
Reactome
2 pathways; mostly iron and oxidative stress0.80
proposal for CYP3A5, translation score 0.56

Knock down and overexpress CYP3A5 in a dopamine neuron, astrocyte and microglia tri-culture; measure reactive oxygen species (CellROX) and lipid peroxidation and labile iron and dopamine neuron survival after α-synuclein fibril challenge.

Cell type
a dopamine neuron, astrocyte and microglia tri-culture
Direction
Both arms: public data does not say which way helps; existing compounds already reach the inhibition arm.
Molecular readout
reactive oxygen species (CellROX) and lipid peroxidation and labile iron
Functional readout
dopamine neuron survival after α-synuclein fibril challenge
Rule-out
If neither arm moves reactive oxygen species (CellROX) by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
Lab request
CRISPRi knockdown and lentiviral overexpression of CYP3A5 in a tri-culture of iPSC dopamine neurons, astrocytes and microglia; n = 3 differentiations; readouts: reactive oxygen species (CellROX) and lipid peroxidation and labile iron; dopamine neuron survival after α-synuclein fibril challenge. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.

Sealed predictions

  1. CYP3A5 in dopamine neurons, braak+0.22 (p 0.563) → -0.19 (p 0.618)receipt 9803

Swarm cases

receipt 9803: CYP3A5 in dopamine neurons, braak

power
full sample +0.17 (p 0.493, n 18), 95% CI -0.32 to +0.59. the interval is wide: not enough donors to tell.
confounder
adjusted for sex: +0.20 (p 0.418, n 18). does not hold up.
composition
dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.18 (p 0.471, n 18). could be the mix.
skeptic
leave-one-out range +0.07 to +0.32, sign flips 0; without severely affected donors +0.17 (p 0.493, n 18). fragile.
cell type
no other cell group does better.
axis
no measure beats "tracks Braak Lewy-body stage" for CYP3A5 in dopamine neurons.

case closed: nothing better to follow up.

Receipts

loading the receipts